Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26259534 | 0.78 | KIF11 (0.30) | KIF11 | |
| SCHEMBL8306245 | 0.76 | IDO1 (0.47) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30708547 | 0.76 | IDO1 (0.47) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1948580 | 0.73 | IDO1 (0.42) | CYP1A2CYP2C19 | |
| SCHEMBL26259686 | 0.73 | — | — | |
| SCHEMBL26259398 | 0.72 | MEN1 (0.33) | — | |
| SCHEMBL26259557 | 0.72 | IKBKE (0.32) | — | |
| SCHEMBL1501942 | 0.72 | IDO1 (0.47) | ALDH1A1TDP1CYP3A4MAPTHSD17B10 | |
| SCHEMBL9258894 | 0.72 | KDM4E (0.50) | ALDH1A1TSHRTDP1CYP1A2TP53 | |
| SCHEMBL1501919 | 0.72 | IDO1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9765068-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8940726-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TRPA1 4530/4885ALDH1A1 1890/4885TSHR 4074/4885 |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TRPA1 4744/4885ALDH1A1 2460/4885TSHR 3498/4885 |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TRPA1 4744/4885ALDH1A1 2460/4885TSHR 3498/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TRPA1 4736/4885ALDH1A1 2705/4885TSHR 3733/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | TRPA1 4530/4885ALDH1A1 1890/4885TSHR 4074/4885 |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TRPA1 4744/4885ALDH1A1 2460/4885TSHR 3498/4885 |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TRPA1 4744/4885ALDH1A1 2460/4885TSHR 3498/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TRPA1 4530/4885ALDH1A1 1890/4885TSHR 4074/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TRPA1 4792/4885ALDH1A1 3825/4885TSHR 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.